Microbiology diagnostics devices and equipment are a broad category covering all kinds of items used in microbiology laboratories and used to diagnose infectious diseases by examining pathogens. These devices and equipment included microscopes, slides, test tubes, Petri dishes, growth media (liquid and solid), inoculation loops, pipettes, and tips, incubators, autoclaves, and laminar flow hoods. Some pieces of equipment are permanent, like microscopes and hoods, while others are not, like pipette tips. The main types of microbiology diagnostic devices and equipment are laboratory instruments, and microbiology analyzers. Laboratory instruments are types of instruments such as incubators, gram stainers, bacterial colony counters, petri dish fillers, and automated culture systems that are needed for operations in the laboratories. The micro-biology analyzers involved are microbiology diagnostics instruments and microscopes. The reagents are pathogen-specific kits, and general reagents. The end-users involved are hospitals, diagnostic centres, customer lab service providers, academic institutes, and research institutes. The microbiology diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides microbiology diagnostics devices and equipment market statistics, including microbiology diagnostics devices and equipment industry global market size, regional shares, competitors with a microbiology diagnostics devices and equipment market share, detailed microbiology diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the microbiology diagnostics devices and equipment industry. This microbiology diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global microbiology diagnostic devices and equipment market size will grow from $3.94 billion in 2022 to $4.43 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global microbiology diagnostic devices and equipment market size is expected to grow from $6.35 billion in 2027 at a CAGR of 9.4%. Increasing funding of public and private investments in medical devices is driving the growth of the microbiology diagnostic devices market. Increasing Investments indicate the rising confidence of various private and public players on microbiology diagnostic devices, thereby indicating a progressive increase and stimulating growth. For instance, according to MedTech news, a publisher of new related to medical technology, private equity industry invested $111.8 B (c.$ 151 B) in healthTech industry. Furthermore, globally 96 deals valued at $40.8 billion were completed in medTech vertical. The increasing investments in digital health technologies, artificial intelligence and non-invasive monitoring capability, delivery of gene therapy and regenerative medicines technologies, and customized 3D printing of medical devices are expected to drive the microbiology diagnostic devices market. Unfavourable regulatory scenarios are major restraints in the microbiology diagnosis devices market. In the US, section 510(k) of the Food, Drug, and Cosmetic Act states that every device manufacturer must register with FDA and notify their intent to market a medical device at least 90 days in advance. These pre-market notifications are considered to be lengthy, rigorous, and time-consuming processes for the approval of medical devices. If in case the submission fails due to some uncertainty, the company has to reperform all the tests and resubmit the premarket approval application. For instance, a 'Verticle Autoclave', a microbiology diagnostic device, complies with the strict international directives and standards such as the capacity of 80-120 litre autoclave chamber volume, low sensitivity loads, restrictions on temperature calibration, and a certificate from ISO17025 accreditation lab for temperature, pressure gauges & timer. Next-Generation Sequencing (NGS) technologies are increasing their prevalence in the microbiology diagnostic devices market due to their cost effectiveness, sensitivity to detect low-frequency variants, and comprehensive genomic coverage. Next-Generation Sequencing (NGS) or high throughput sequencing or Massively Parallel Sequencing (MPS) is a method of sequencing genomes with the ability to sequence hundreds to thousands of genes or gene regions and the capability to detect novel resistance genes (ARG) in bacteria. BioMérieux partnered with Illumina to develop bioMérieux EpiSe, an NGS service that will facilitate epidemiological monitoring of bacterial infections and monitor outbreaks in hospitals. Some of the modern next-generation sequencing technologies that help to sequence DNA and RNA include Illumina (Solexa) sequencing, Roche 454 sequencing, Ion torrent Proton / PGM sequencing, and SOLiD sequencing. On May 26th, 2022, The IVD Regulation seeks to ensure a high level of public health and patient safety taking into account scientific progress, and smooth operation of the single market for these products. These changes by the EU legislation aid in the development of microbiology diagnostic devices, as they focus on providing transparency of information through EUDAMED (the new European database of medical devices), allowing manufacturers to monitor products, stronger clinical evidence, post-market surveillance, and enhance safety improvements. In April 2022, DCN Dx, a US-based manufacturer and developer of point-of-use tests, acquired Biomed Diagnostics for an undisclosed amount. The acquisition would expand DCN Dx’s footprint in the vertical of point-of-use testing and sampling markets for both humans and animals.Biomed Diagnostics is a US-based microbiological testing company. Major players in the microbiology diagnostics devices and equipment market are Becton Dickinnson and Company, Biomerieux, Danaher, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories Inc., Bruker Corporation, Neogen Corporation, Merck KGaA, and Charles River Laboratories International Inc. North America was the largest region in the microbiology diagnostics devices and equipment market in 2022. Asia-Pacific was the second largest region in the global microbiology diagnostic devices and equipment market. The regions covered in the global microbiology diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the microbiology diagnostics devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The microbiology diagnostic devices and equipment consists of sales of instruments such as incubators, autoclave sterilizers, anaerobic culture systems, blood culture systems, gram strainers, microscopes, mass spectrometers, molecular diagnostic instruments, reagents pathogen-specific kits, and general reagents for microbiology diagnostic. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global microbiology diagnostic devices and equipment market is segmented - 1) By Type: Laboratory Instruments, Microbiology Analysers 2) By End User: Hospitals, Diagnostic Centres, Customer Lab Service Providers, Academic Institutes, Research Institutes 3) By Laboratory Instruments: Incubators, Gram Stainers, Bacterial Colony Counters, Petri Dish Fillers, Automated Culture Systems 4) By Micro-Biology Analyzers: Microbiology Diagnostics Instruments, Microscopes 5) By Reagents: Pathogen-Specific Kits, General Reagents

Rapid microbiology testing has high sensitivity and less turnover time compared to traditional methods and is used to diagnose infectious diseases or target products by examining pathogens within a short period. The main product types of rapid microbiology testing kits are instruments, reagents, kits, consumables. The various testing types included are growth-based rapid microbiology testing kits, cellular component-based rapid microbiology testing kits, nucleic acid-based rapid microbiology testing kits, viability-based rapid microbiology testing kits, and other rapid microbiology testing kits methods that are used for applications such as clinical disease diagnosis, food, and beverage testing, pharmaceutical and biological drug testing, cosmetics and personal care products testing, environmental testing, research applications, and others. The rapid microbiology testing kits market research report is one of a series of new reports from The Business Research Company that provides rapid microbiology testing kits market statistics, including rapid microbiology testing kits industry global market size, regional shares, competitors with a rapid microbiology testing kits market share, detailed rapid microbiology testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the rapid microbiology testing kits industry. This rapid microbiology testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global rapid microbiology testing kits market grew from $4.36 billion in 2022 to $4.61 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The rapid microbiology testing kits market is expected to grow from $5.78 billion in 2027 at a CAGR of 5.8%. The rising number of infectious diseases is one of the major drivers for the rapid microbiology testing kits market. Rapid diagnostic tests are faster, more reliable, and more widely available than traditional tests. As the number of infectious disease cases increases, the need for tests to confirm these diseases also increases. With the increasing demand for microbiology tests, the need for rapid microbiology tests is increasing as it gives quicker results than normal microbiology tests. For example, according to the Centers for Disease Control and Prevention (CDC) Trusted Source, the number of visits to physician offices with infectious and parasitic diseases as the primary diagnosis was 15.5 million and the number of emergency department visits with infectious and parasitic diseases as the primary diagnosis was 3.7 million per year. The stringent regulations related to rapid microbiology testing kits are a major restraint for the market. This is because scientific validation is a critical part of obtaining regulatory approval for a rapid microbiology testing method. In this regard, various tests such as a test for accuracy, specificity, precision, range, and robustness are mandatory. The processes for evaluating, validating, and implementing rapid microbiology test methods are expensive and time-consuming. This often leads to a delay in the launch of a testing method and adds up to the final cost of the test. For example, the process for approval by the FDA for rapid microbiology testing methods is very time-consuming which alters the normal operating cycle for manufacturers and causes a delay in the commercial launch of the test devices in the market. Technological advancements are an emerging trend in the rapid microbiology testing kits market. This is mainly because these technological advancements improve the reliability and efficiency of tests and testing methods. Automation in rapid microbial detection enables higher throughputs and greater accuracy in results. Similarly, robotic cassette handling, incubation, and imaging reduce the risks of miscounts, mid-test contamination, and incorrect data entry, which leads to fewer false positives and out-of-specification investigations. Fewer investigations then ultimately improve uptime and reduce delay and recall of tests. For example, Abbott Laboratories announced the next generation Alinity HQ Hematology Analyzer that is aimed to minimize errors and reduce manual steps in testing. The FDA regulates rapid microbiology testing through its process analytical technology (PAT) regulatory framework initiative. PAT is a system that evaluates the designing, controlling, and timely measuring of critical quality of raw and processed materials. It seems that manufacturers have built-in quality into products rather than testing quality in products. This ensures final product quality and improves manufacturing efficiencies. Hence, regulations such as these would keep a check on the companies in the rapid microbiology testing market. Major players in the rapid microbiology testing kits market are Abbott Laboratories, Becton, Dickinson and Company, Bruker Corporation, Charles River Laboratories International Inc., Danaher Corporation, Don Whitley Scientific Limited, Merck KGaA, Neogen Corporation, Quidel Corporation, and Rapid Micro Biosystems Inc. North America was the largest region in the rapid microbiology testing kits market in 2022. Western Europe was the second largest region in the global rapid microbiology testing kits market report. The regions covered in global rapid microbiology testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the rapid microbiology testing kits market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The rapid microbiology testing market includes revenues earned by entities by qualitative, quantitative, and identification methods. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global rapid microbiology testing kits market is segmented - 1) By Product Type: Instruments, Reagents And Kits, Consumables 2) By Application: Clinical Disease Diagnosis, Food And Beverage Testing, Pharmaceutical And Biological Drug Testing, Cosmetics And Personal Care Products Testing, Environmental Testing, Research Applications, Other Applications 3) By Testing Type: Growth-Based Rapid Microbiology Testing Kits, Cellular Component-Based Rapid Microbiology Testing Kits, Nucleic Acid-Based Rapid Microbiology Testing Kits, Viability-Based Rapid Microbiology Testing Kits, Other Rapid Microbiology Testing Kits Methods

The pharma microbiology testing kits detect contamination and uphold good standards. They are used to detect the microbial limits among drugs, vaccines, and other biologics. The main products of pharma microbiology testing kits are consumables and equipment. The pharma microbiology testing kits consumables are products used to detect the microbial limits among drugs, vaccines, and other biologics. The various tests performed by pharma microbiology testing kits are endotoxin testing, sterility testing, microbial examination, environmental monitoring, and others that are used by end-users such as hospitals and diagnostic centres, custom lab service providers, and academic and research institutes. The pharma microbiology testing kits market research report is one of a series of new reports from The Business Research Company that provides pharma microbiology testing kits market statistics, including pharma microbiology testing kits industry global market size, regional shares, competitors with a pharma microbiology testing kits market share, detailed pharma microbiology testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the pharma microbiology testing kits industry. This pharma microbiology testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pharma microbiology testing kits market grew from $5.66 billion in 2022 to $6.25 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharma microbiology testing kits market is expected to grow from $8.78 billion in 2027 at a CAGR of 8.8%. The rise in the incidence of infectious diseases is one of the prime drivers of the pharma microbiology testing kits market. According to CDC (Centre for Disease Control and Prevention), infectious diseases such as Hepatitis A, B, and C, sexually transmitted diseases (STDs), and human immunodeficiency virus (HIV) are increasing their prevalence globally. WHO report indicated that there were about 1.4 million cases of Hepatitis A reported globally every year. Hence the increasing number of infectious disease cases due to infected needle injections, unprotected sex, homelessness, lack of access to medical care, and other socioeconomic challenges drive the pharma microbiology testing kits market. The limited shelf life of microorganisms and microbiology reagents acts as a major restraint on the pharma microbiology testing kits market. Shelf life is defined as the time for which a product remains fit for use after its generation. The shelf life of microbiology reagents depends upon exposure to atmospheric conditions. The life of microorganisms such as bacteria (only 12hours) is short therefore the time for microbiological research is very limited as the quality of microorganisms deteriorates and becomes unfit to use resulting in inaccurate pharma microbiology testing kits results. Hence, the short or limited shelf life of microbiology reagents may increase cost and hamper the pharma microbiology testing kits market growth. Outsourcing of microbiological testing to contract testing laboratories is becoming popular in the pharma microbiology testing kits market. Outsourcing of routine microbiological testing activities controls and ensures better quality and safety of raw materials, intermediates, and finished products. The contract testing laboratories are outsourced with some testing areas such as stability testing, raw material testing, method validation, microbial testing, environmental monitoring, physical characterization, batch-release testing, bioanalytical testing, and others. For instance, the global healthcare analytical testing market is projected to expand to $4.13 billion by 2021 at a growth rate of 11.3%. Food and Drug Administration (FDA) is a federal agency and regulatory body for the pharma microbiology testing kits market in the United States department of health and human services. Laboratories and food companies across the globe use these standards to make sure that food products are safe to eat and drink. FDA's Bacteriological Analytical Manual (BAM) detects pathogens (bacterial, viral, parasitic, plus yeast and mold) in food and cosmetic products. Enhanced standards for microbial testing, additional microbiological methods, and environmental testing methods have been set by FDA to ensure food and drug safety. In November 2022, IDEXX, a US-based healthcare innovation company, acquired Tecta-PDS for an undisclosed amount. The acquisition would allow IDEXX to expand its footprint in water microbiology testing. Tecta-PDS is a Canada-based water microbiology testing company. Major players in the pharma microbiology testing kits market are F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Abbott Laboratories, ThermoFisher Scientific, Lucideon, SGS SA, ToxiKon, Pace Analytical Services, Boston Analytics, Charles River Laboratories International, and Nelson Laboratories. North America was the largest region in the pharma microbiology testing kits market in 2022. Western Europe was the second largest region in the global pharma microbiology testing kits market report. The regions covered in the global pharma microbiology testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pharma microbiology testing kits market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The pharma microbiology testing kits market consists of sales of rapid test systems, common rapid test kits, rapid tests for salmonella, PCR test, and lateral flow. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharma microbiology testing kits market is segmented - 1) By Product: Consumables, Equipment 2) By Test: Endotoxin Testing, Sterility Testing, Microbial Examination, Environmental Monitoring, Other Tests 3) By End User: Hospitals & Diagnostic Centers, Custom Lab Service Providers, Academic & Research Institutes

Antimicrobial susceptibility testing (AST) is a laboratory procedure done by clinical laboratory professionals to identify which antimicrobial specimen is specifically effective for individual patients. The antimicrobial susceptibility testing market consists of sales of antimicrobial susceptibility testing by entities (organizations, sole traders and partnerships) that are engaged in laboratory services that provide antimicrobial susceptibility testing. The main types of antimicrobial susceptibility testing (AST) procedures are antibacterial testing, antifungal testing, antiparasitic testing and others. Antifungal susceptibility testing refers to the ability of a specific organism to grow in vitro in the presence of a particular drug. AST products that are used in the testing are manual antimicrobial susceptibility testing products, automated laboratory instruments, and other consumables. These are used for diagnostics, drug discovery and development, and epidemiology. Antimicrobial susceptibility testing is used by hospitals and diagnostic centres, pharmaceutical and biotechnology companies, research and academic institutes, and clinical research organizations (CROs). The antimicrobial susceptibility testing market research report is one of a series of new reports from The Business Research Company that provides antimicrobial susceptibility testing market statistics, including antimicrobial susceptibility testing industry global market size, regional shares, competitors with an antimicrobial susceptibility testing market share, detailed antimicrobial susceptibility testing market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial susceptibility testing industry. This antimicrobial susceptibility testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antimicrobial susceptibility testing market size grew from $3.67 billion in 2022 to $3.91 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antimicrobial susceptibility testing market size is expected to grow to $4.94 billion in 2027 at a CAGR of 6.0%. The rising incidence of infectious diseases globally contributed to the growth of the antimicrobial susceptibility testing market. Infectious diseases are caused by organisms like bacteria, viruses, fungi and parasites. Diseases caused by bacteria are bacterial pneumonia, tuberculosis, the virus smallpox, AIDS and others. According to World Health Organization (WHO), in 2021, , an estimated 10.6 million people are infected with tuberculosis globally, 1.6 million died , and 1.5 million people acquired HIV in 2021 while 650,000 people lost lives due to it. This increase in the incidence of infected people boosted the use of susceptibility testing of the organisms to develop the most effective drugs and this, in turn, drove the market for antimicrobial susceptibility testing. Rapid antimicrobial susceptibility testing is increasingly being used to avoid misuse of antibiotics and to provide effective treatment and this is emerging as a key trend in the antimicrobial susceptibility testing market. There are many ways to perform antimicrobial susceptibility testing in minutes or a few hours. FISH (Fluorescence in situ hybridization) is mostly used in rapid antimicrobial susceptibility testing. The PNA-FISH applies peptide nucleic acid probes that allow rapid and specific binding, this process is applied in QuickFish technology (OpGen) which performs identification of microbial by targeting 16s RNA. For instance, the antimicrobial susceptibility testing system by Genefluidics Inc measures bacterial growth by quantifying 16s rRNA molecules using an electrochemical biosensor. Major players in the antimicrobial susceptibility testing market are BioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Accelerate Diagnostics, Hi-Media Laboratories, Creative Diagnostics, Merck KGaA, Roche Diagnostics Limited, BD, Alifax Holding S.p.A., Synbiosis, Zhuhai DL Biotech Co, Mast Group, ELITechGroup, Genefluidics, Mast Group, CONDALAB, and QuantaMatrix. North America was the largest region in the antimicrobial susceptibility testing market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the antimicrobial susceptibility testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the antimicrobial susceptibility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimicrobial susceptibility testing (AST) market includes revenues earned by dilution susceptibility tests and disc diffusion susceptibility tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antimicrobial susceptibility testing market is segmented - 1) By Type: Antibacterial Testing, Antifungal Testing, Antiparasitic Testing, Other Types 2) By Products: Manual Antimicrobial Susceptibility Testing Products, Automated Laboratory Instruments, Consumables 3) By Application: Diagnostics, Drug Discovery and Development, Epidemiology, Other Applications 4) By End User: Hospitals And Diagnostic Centers, Pharmaceutical And Biotechnology Companies, Research And Academic Institutes, Clinical Research Organizations (CROs)

Microbiome refers to a group of microbes that live in a certain habitat and include fungi, bacteria, and viruses. It is all of the bacteria, fungi, protozoa, and viruses' genetic material that dwells on and within the human body. The microbiome's bacteria also aid in digestion, immune system control, defence against disease-causing bacteria, and the production of vitamins like Vitamin K, which is required for blood clotting, and the B vitamins B12, thiamine, and riboflavin. The main types of microbiomes are faecal microbiota transplantation (FMT) and microbiome drugs. The technique of transferring faecal bacteria and other germs from one healthy person to another is known as faecal microbiota transplantation or stool transplantation. The different technologies include genomics, proteomics, and metabolomics and are used in inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, and others. The microbiome market research report is one of a series of new reports from The Business Research Company that provides microbiome market statistics, including microbiome industry global market size, regional shares, competitors with a microbiome market share, detailed microbiome market segments, market trends, and opportunities, and any further data you may need to thrive in the microbiome industry. This microbiome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global microbiome market size will grow from $0.39 billion in 2022 to $0.57 billion in 2023 at a compound annual growth rate (CAGR) of 45.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global microbiome market size is expected to grow from $1.09 billion in 2027 at a CAGR of 17.6%. The increasing prevalence of inflammatory bowel disease (IBD) is a key factor driving the growth of the microbiome market. Inflammatory bowel disease (IBD) is a multifactorial and autoimmune infection group consisting of two major entities such as ulcerative colitis (UC) and Crohn's disease (CD). Fecal microbiota transplantation (FMT) and probiotics were discovered as having potential applications in many immune-mediated disorders, such as IBD, to restore microbial balance. These microbial therapies have shown the potential to reduce both the dysbiotic condition and the development of inflammatory mediators, thereby enabling remission, particularly in UC. For instance, in September 2020, according to the National Institute of Health, a US-based biomedical and public health research agency, between 600,000 and 900,000 Americans may suffer from ulcerative colitis. Therefore, the increasing prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the microbiome market. The high cost of microbial therapy is a key factor hampering the growth of the microbiome market. The price of fecal transplantation, a microbial therapy, may vary considerably depending on the delivery method used by users and where users receive it. Fecal microbiota transplant processes can charge around $600-$1,000 based on the method of treatment, area, insurance coverage, and other variables. Therefore, the high cost of microbial therapy is expected to hinder the growth of the microbiome market. The growing technological improvement is a major trend gaining popularity in the microbiome market. Major companies in the microbiome sector are focusing on developing advanced technology solutions for microbiomes. For instance, Seed, a new microbiome company, has introduced Probiotic and Prebiotic Daily Synbiotic for both females and males. The Daily Synbiotic Seed is the first to follow a microbe-system strategy with strain-specific advantages beyond digestive health such as cardiac safety, dermatological health, immune control, reproductive health, the integrity of the gut barrier, and oxidative stress. In January 2021, Novozymes, a Denmark-based biotechnology company, acquired Microbiome Labs for an undisclosed amount. Microbiome Labs’ acquisition is a crucial step in expanding Novozymes’ Human Health platform, giving it exposure to a wide range of patented solutions as well as access to the firm’s network of health professionals. Microbiome Labs is a probiotics company based in the United States. Major players in the microbiome market are MicroBiome Therapeutics LLC., Seres Therapeutics, Enterome Bioscience, Second Genome, Vedanta Biosciences Inc., AbbVie Inc., Rebiotix, Inc., Ritter Pharmaceuticals, LNC Therapeutics Inc., and ViThera Pharmaceuticals Inc. North America was the largest region in the microbiome market in 2022. The regions covered in the global microbiome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the microbiome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The microbiome market consists of sales of firmicutes, bacteroidetes, and actinobacteria. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global microbiome market is segmented - 1) By Type: Fecal Microbiota Transplantation (FMT), Microbiome Drugs 2) By Application: Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Other Applications 3) By Technology: Genomics, Proteomics, and Metabolomics

In-vitro diagnostics devices and equipment is a gadget that tests human samples collected from the human body such as tissues and blood, with the goal of using the results to help with clinical diagnosis or management. The main types of in-vitro diagnostics equipment are point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices, and equipment, and immunohematology diagnostic devices, and equipment. Hematology instruments are machines that analyze blood. The hematology instruments perform blood counts, detect proteins or enzymes, and help to diagnose illnesses or genetic defects. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The end-users are hospitals and clinics, diagnostic laboratories, and others. The in-vitro diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides in-vitro diagnostics devices and equipment market statistics, including in-vitro diagnostics devices and equipment industry global market size, regional shares, competitors with a in-vitro diagnostics devices and equipment market share, detailed in-vitro diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro diagnostics devices and equipment industry. This in-vitro diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global in-vitro diagnostics market grew from $95.6 billion in 2022 to $106.53 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The in-vitro diagnostics market is expected to grow to $148.58 billion in 2027 at a CAGR of 8.7%. Demand for point-of-care diagnostic devices is increasing as they provide rapid results, are cost-effective, and have advanced diagnosis features for patients. The number of patients seeking treatments at local physician offices, retail clinics, and in-patient homes is increasing thus boosting the demand for point-of-care testing devices. Companies in this market are focusing on developing more user-friendly, reliable, and efficient point of care devices. For instance, in March 2020, Abbott launched Novel COVID-19 Test. The test will be used on the m2000 RealTime system available in hospitals and molecular labs in the U.S. Philips also launched a new handheld blood test, Handheld Minicare I-20 system used for diagnosing heart attacks in emergency departments which provide results within 10 minutes. IVD devices are being integrated with IoT and data analytics technologies to improve device efficiency and increase device security. IoT refers to a system of interconnected devices via communication technologies such as WIFI and Bluetooth for data transfer and accessing devices remotely. Data analytics refers to qualitative and quantitative techniques, used to infer actionable information from large data sets. These technologies are helping in enhancing IVD device functionality, mainly through remote monitoring, predictive maintenance for decreased downtime, and advanced data processing capabilities. Major companies in the in-vitro diagnostics devices and equipment market include Siemens Healthineers, F. Hoffmann-La Roche Ltd., Danaher (Beckman Coulter Inc), Abbott Laboratories Inc., and Thermo Fisher Scientific Inc. North America was the largest region in the global in-vitro diagnostics market in 2022. Asia-Pacific was the second largest region in the global in-vitro diagnostics market. The regions covered in the in-vitro diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the in-vitro diagnostics devices and equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The in-vitro diagnostics devices and equipment market consist of sales of kits, reagents, piece of software, system, and instrument. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global in-vitro diagnostics market is segmented - 1) By Type: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

The molecular diagnostics market consists of sales of molecular diagnostics services and related products by entities (organizations, sole traders, partnership) that are utilised to direct patient management, from diagnosis to treatment, especially in the treatment of congenital anomalies, infectious diseases, and cancer. Molecular diagnostic is a term used to describe a class of techniques that are used to examine biological markers in the genetic code (genome) of an organism and to determine how its cells express their genes as proteins. The main types of products in molecular diagnostics are instruments, reagents, consumables, software, and services. Instruments refer to a measuring device for determining the present value of a quantity under observation. The technologies include polymerase chain reaction (PCR), DNA sequencing, and next-generation sequencing, and these are used in oncology, pharmacogenomics, infectious diseases, genetic testing, neurological disease, cardiovascular disease, microbiology, and other applications. The various end-users are hospitals, laboratories, and other end-users (blood banks, home health agencies, and nursing homes). The global molecular diagnostics market size is expected to grow from $49.49 billion in 2021 to $49.64 billion in 2022 at a compound annual growth rate (CAGR) of 0.3%. The global molecular diagnostics market size is expected to decline to $47.78 billion in 2026 at a compound annual growth rate (CAGR) of -1.0%. The rising prevalence of infectious diseases and cancers of different forms drives the molecular diagnostics market. To determine whether mutations to a gene or chromosome may raise a person's chance of acquiring cancer or other disorders, molecular testing is employed. The increasing prevalence of infectious diseases and various types of cancer creates a demand for new diagnostic procedures, including fast and specific molecular diagnostic tests. For instance, in 2020, according to the National Cancer Institute, a US-based government agency, an estimated 1,806,590 new cases of cancer would be diagnosed in the United States and 606,520 people would die from the disease. Therefore, the increasing prevalence of cancer is driving the growth of the molecular diagnostic market. The advances in genomics and proteomics are a key trend gaining popularity in the molecular diagnostics market. Polymerase chain reaction (PCR) is a recent development in genomics and helps in discovering new approaches to molecular diagnosis for disease diagnosis and pathogenesis of diseases. This enables better monitoring and a fast diagnosis and major organizations are investing to have a competitive edge. Following the trend, $600 million to support the COVID-19 vaccine and therapy clinical trials led by the private sector and for Canadian bio-manufacturing opportunities. This announcement was part of the $1 billion Plan to Mobilize Science. The growing research in proteomics and genomics will help develop more advanced molecular diagnostic techniques in the forecast period. In April 2021, Hologic, a US-based women’s health technology company, acquired Mobidiag Oy for an undisclosed amount. The acquisition would accelerate the global growth of Mobidiag’s molecular diagnostic test platforms, which offer ease of use, multiplex capability, and rapid turnaround time. Mobidiag Oy is a Finland-based company that develops and provides molecular diagnostics for infectious diseases and antibiotic resistance. The major players in the molecular diagnostics market are Becton, BioMérieux SA, Danaher Corporation, Grifols, Hologic Inc., Novartis AG, QIAGEN, Siemens Healthcare GmbH, Abbott, and Dickinson and Company. North America was the largest region in the molecular diagnostics market in 2021. The regions covered in the global molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the molecular diagnostics market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The global molecular diagnostics market is segmented - 1) By Technology: Polymerase Chain Reaction (PCR), DNA Sequencing, and Next-Generation Sequencing 2) By Product: Instruments, Reagents and Consumables, Software and Services 3) By Application: Oncology, Pharmacogenomics, Infectious Diseases, Genetic Testing, Neurological Disease, Cardiovascular Disease, Microbiology, and Others 4) By End-User: Hospitals, Laboratories, and Others (Blood Banks, Home Health Agencies, and Nursing Homes)

The microbiome therapeutics market consists of sales of microbiome therapeutics and related services by entities (organizations, sole traders, partnership) which are used to treat and prevent various diseases. The microbiome comprises the genetic material within a microbiota which is an entire collection of microorganisms found in and on all multicellular organisms. The main products of microbiome therapeutics are probiotics, prebiotics, symbiotics, and other products. Probiotics are a combination of live beneficial bacteria and/or yeasts that naturally live in the body. The various distribution channels involved are hospital pharmacies, drug stores, retail pharmacies, and e-commerce stores. The applications included are inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, and other applications. The global microbiome therapeutics market size is expected to grow from $0.29 billion in 2021 to $0.39 billion in 2022 at a compound annual growth rate (CAGR) of 34.7%. The global microbiome therapeutics market size is expected to grow to $1 billion in 2026 at a compound annual growth rate (CAGR) of 26.4%. The rising prevalence of obesity is expected to propel the growth of the microbiome therapeutics market. Sedentary lifestyles, busy work lives, and unhealthy food choices are gradually becoming the leading causes of obesity globally. Growing urbanization and busy lifestyles are leading to an increasing preference for packaged and processed foods and physical inactivity. Microbiome therapeutics help prevent and treat diabetes by regulating sugar levels. For instance, in 2022, according to the UK Parliament, a survey found that men are more likely than women to be overweight or obese (68.2% of men, 60.4% of women). People aged 45–74 are most likely to be overweight or obese. Therefore, the rising prevalence of obesity is driving the growth of microbiome therapeutics. Increased research and development is a key trend gaining popularity in the microbiome therapeutics market. Companies operating in the microbiome therapeutics market are focused on developing new innovations to increase their market share. For instance, in March 2022, Microbiotica, a UK-based company, raised $67 million in a Series B round to push two microbiome-based lead assets through phase 1b trials, slated to start this year. In April 2022, Xbiome Inc., a China-based artificial intelligence microbiome therapeutics startup, acquired a clinical-stage M201 program from Assembly Biosciences, Inc. for an undisclosed amount. This acquisition reflects Xbiome’s commitment as one of the leaders in the rising field of microbiome therapeutics. Assembly Biosciences, Inc. is a US-based clinical-stage biotechnology company. Major players in the microbiome therapeutics market are Seres Therapeutics, Enterome Bioscience, Rebiotix, Microbiome Therapeutics, and Ritter Pharmaceuticals. North America was the largest region in the microbiome therapeutics market in 2021. The regions covered in the global microbiome therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the microbiome therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global microbiome therapeutics market is segmented - 1) By Product: Probiotics, Prebiotics, Symbiotics, and Others 2) By Application: Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, and Others 3) By Distribution Channel: Hospital Pharmacies, Drug stores, Retail Pharmacies, and E-commerce stores